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PRM6
The AccePTAnce Of MORbidiTy endPOinTs in The AMnOg PROcess 
in geRMAny: ARe TheRe gReATeR huRdles fOR subsTAnces WiThin 
OncOlOgy?
Bakker K, Volmer T
SmartStep Consulting GmbH, Hamburg, Germany
Objectives: The objective of this study is to assess the acceptance of morbidity 
endpoints by the Institute for Quality and Efficiency in Healthcare (IQWiG) within 
the early benefit assessment in Germany. The analysis focuses on morbidity end-
points (ME) for oncology substances compared to non-oncology substances: (1) 
how many ME have been accepted? (2) In how many cases has IQWiG determined 
an additional benefit based on ME? MethOds: All benefit assessments published 
by the Federal Joint Committee (G-BA) between 01/01/2011 and 12/05/2015 have 
been considered (n= 126). Of those, 80 were excluded from the analysis due to 
one of the following reasons: orphan drug designation, no dossier submitted or 
incomplete evaluation by the IQWiG (due to missing data). Data analyzed: num-
ber of accepted ME as proportion of all submitted endpoints; additional benefit 
based on accepted ME; percent of assessments in which at least one ME was 
accepted. Results: In total, 19 oncology and 27 non-oncology assessments 
have been included into the analysis. For the 19 oncology assessments, a total 
of 76 ME had been submitted. IQWiG accepted hereof 20 ME (≈26%). Accepted ME 
include: pain, skeletal-related complications and symptoms. The IQWiG deter-
mined an additional benefit for six assessments based on ME (6/19≈32%). For the 
27 non-oncology assessments, 127 ME had been submitted. IQWiG accepted 79 
(≈62%) including: strokes, cardiovascular events and relapse-related events. For 
non-oncology substances, IQWiG determined an additional benefit for thirteen 
assessments based on ME (13/27≈48%). At least one endpoint was accepted in 
83% of oncology assessments and in 100% of benefit assessments in all other 
indications. cOnclusiOns: Though the rate of accepting ME in oncology indica-
tions is numerically lower (32% vs. 48%), the difference does not reach statistical 
significance (p= 0.36 Fisher’s exact test).
PRM7
cOMPARisOn Of TReATMenT-RelATed AdveRse evenTs RecORded in 
AdMinisTRATive clAiMs dATA WiTh ThOse RecORded in elecTROnic 
MedicAl RecORds fOR MulTiPle MyelOMA PATienTs
Irwin DE1, Varker H2, Farr AM2
1Truven Health Analytics, Chapel Hill, NC, USA, 2Truven Health Analytics, Bethesda, MD, USA
Objectives: Multiple myeloma patients often experience adverse events 
(AEs) related to treatment with novel therapies or traditional chemotherapy. 
Observational studies frequently use administrative claims data or electronic medi-
cal records (EMR) to assess potential AEs. The purpose of this analysis is to compare 
the occurrence of AEs identified in claims data with those recorded in an oncol-
ogy EMR. MethOds: Multiple myeloma cases (n= 278) in the MarketScan Oncology 
EMR-Claims Linked Dataset who received novel or traditional chemotherapy were 
included. The index date was the first date of medication administration/order and 
patients were followed for AEs, including neutropenia, thrombocytopenia, venous 
thromboembolism (VTE) and diarrhea, until a > = 90 gap in all medications for the 
first regimen. Results: Neutropenia and thrombocytopenia were recorded less 
often in claims (neutropenia 9%; thrombocytopenia 7%) compared to EMR data 
(neutropenia 12%; thrombocytopenia 11%). Neutropenia and thrombocytopenia are 
monitored by oncologists with lab values and this may lead to more frequent record-
ing of less severe AEs in the EMR not reflected in claims data. VTE and diarrhea were 
recorded more often in the claims (VTE 9%; diarrhea 7%) compared to the EMR (VTE 
4%; diarrhea 4%). A VTE diagnosis may likely result in hospitalization and patients 
with diarrhea may seek care outside of their oncology practice; hence, claims data 
may capture additional diagnoses assigned by clinicians other than oncologists. 
Overall, the highest proportions of AEs were found with the linked data contain-
ing both the claims and EMR (neutropenia 19%, thrombocytopenia 16%, VTE 10%, 
diarrhea 11%). cOnclusiOns: AEs typically monitored by lab values ordered by 
oncologists were recorded more often in EMR data and AEs potentially diagnosed by 
clinicians in settings outside the oncology practice were recorded more often in the 
claims data. The linked claims-EMR data provided the most complete assessment 
of potential treatment-related AEs.
PRM8
nOn-cOMPARATive TRiAls TO suPPleMenT neTWORk MeTA-AnAlyses 
using ARM-sPecific MeTA-RegRessiOn: An APPlicATiOn TO cOMbinATiOn 
TheRAPies in hiv
Kanters S1, Druyts E2, Jansen JP3, Mills EJ4, Thorlund K1
1Redwood Outcomes, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, 
Canada, 3Redwood Outcomes, San Francisco, CA, USA, 4Stanford University, Stanford, CA, USA
Objectives: There is a growing call for the use of endonodal trials within network 
meta-analyses (NMA), such as for informative priors or improved connectivity. 
Endonodal trials can also be used to further inform arm-specific meta-regression 
coefficients, which may be used to simplify node definitions in combination therapy. 
We applied this concept to a network of first line antiretroviral therapy (ART) to 
determine if efavirenz (EFV) still belongs in the preferred regimen. MethOds: We 
conducted a systematic search of electronic databases up to March 1, 2015. Nodes 
were defined as specific antivirals rather than ART regimens, which simplified 
interpretation of modeling and results. Backbone regimens were categorized and 
arm-specific meta-regression used to adjust estimates accordingly. The alterna-
tive approach was to simply reduce the evidence base to trials that did not differ 
with respect to backbones. The most notable trial to differ in backbones was the 
SINGLE trial comparing EFV to dolutegravir (DTG), central to the research ques-
tion. Results: A total of 71 trials with 35,270 randomized patients informed the 
evidence base. DTG was found to be superior with respect to viral suppression at all 
time points (odds ratio [OR]: 1.87 at 48 weeks; 95% credible interval [CrI]: 1.34 – 2.64). 
Both DTG (OR: 0.26; 95% CrI: 0.15, 0.44) and low-dose EFV (OR: 0.39; 95% CrI: 0.17, 0.83) 
1The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, 2GE Healthcare, Chalfont 
St Giles, UK, 3GE Healthcare, Marlborough, MA, USA, 4CTI Clinical Trial and Consulting Services, 
Cincinnati, OH, USA
Objectives: The decision to utilize a particular product may depend on for-
mal hospital guidelines, physician practice patterns, negotiated reimbursement 
schedules with insurance companies, and other local (geographic and/or hospi-
tal) characteristics. These elements are mostly unobservable for the purpose of 
statistical inference. A hospital fixed-effects model specification, in essence, con-
trols for unobservable within-hospital time-invariant characteristics. Focusing on 
the relationship between iso-osmolar contrast media (CM) and low-osmolar CM 
agents (LOCM) and renal failure events in patients undergoing inpatient inter-
ventional procedures, this study highlights the importance of controlling for such 
factors by comparing statistical specifications with and without hospital fixed-
effects. MethOds: The Premier database was used to identify patients between 
January 2008 and September 2013. Eligible patients had a primary procedure of 
angioplasty defined by International Classification of Diseases, 9th Revision (ICD-
9) and/or Current Procedural Terminology (CPT®) codes, inpatient admission, and 
LOCM or iso-osmolar CM agent. Renal failure during the visit was determined by 
ICD-9 diagnosis codes. Two different statistical approaches were employed to assess 
the relationship between renal failure and CM use – Ordinary Least Squares (OLS) 
cross-sectional and hospital fixed-effects model specification. Results: A total of 
385,290 interventional procedure visits met the inclusion criteria. The unadjusted 
univariate analysis showed 1.7% (p< 0.01) more renal events in the iso-osmolar 
CM cohort compared to LOCM. The most saturated (OLS) cross-sectional analysis 
showed 1.4% (p< 0.01) fewer renal events in the iso-osmolar CM cohort compared 
to patients who received LOCM. Controlling for unobserved heterogeneity across 
hospitals using the most saturated hospital fixed-effect specification, we found 
2.3% (p < 0.01) fewer renal failure events with iso-osmolar CM. cOnclusiOns: This 
study illustrated the importance of controlling for observable and for unobserv-
able, within-hospital time invariant characteristics through a hospital fixed-effects 
specification when the decision-making factors for selection of CM may vary from 
hospital to hospital.
PRM4
A sTudy On cyTOgeneTic And MOleculAR AnAlysis Of PResenilin 1 (Ps1) 
gene in AlzheiMeR’s diseAse
Mohana Devi S1, Sasikala K2, Balachandar V2
1Dankook University, Chungnam, South Korea, 2Bharathiar University, Coimbatore, India
Objectives: Alzheimer’s disease (AD), the most common form of dementia, is a 
degenerative disorder of the brain that leads to memory loss. Oxidative stress is a 
hallmark of AD. This study aims to identify the genetic alterations of AD by using the 
conventional cytogenetic technique by Trypsin G- banding and molecular analysis 
of presenilin 1 (PS1) genotype by PCR. The role of selected ions related to energy 
metabolism as a consequence of oxidative stress in the deterioration accompa-
nied in AD patients were also analyzed. MethOds: The present study includes 
49 AD patients and the subjects were categorized in two groups (14 Early-Onset 
AD) patients and (31 Late- Onset AD) patients, in order to investigate the possible 
cytogenetic and molecular damage. The gels were developed by staining with silver 
nitrate. Results: The Late- Onset AD patient shows higher total CA level when 
compared to Early-Onset AD patient. A comparison of the frequencies for PS1 geno-
types among the Early-Onset AD and Late- Onset AD subjects demonstrated a sig-
nificant difference between the two groups. cOnclusiOns: The strong association 
of PS1 with Late- Onset AD patients called attention to the importance of genetic 
studies in AD and the possible roles of PS1 in the progression of this disease. Based 
on the contributing effects of PS1 in AD pathogenesis, targeting PS1 may provide new 
opportunities for AD therapeutic strategies. Key Words: Early-Onset Alzheimer’s 
disease patient, Late- Onset Alzheimer’s disease patients, PS1, PCR – RFLP
PRM5
hOW gOOd ARe PhysiciAns And chART RevieWs AT cAPTuRing heAlTh 
ResOuRces And dRug uTilisATiOn by PATienTs? ResulTs Of The PgRx-3 
PROsPecTive ReAl WORld dATAseT vAlidATiOn sTudy
Grimaldi-Bensouda L1, Rossignol M2, Worsfold A3, Nordon C1, Abenhaim L3
1LASER Research, Paris, France, 2McGill University, Montreal, QC, Canada, 3LASER Analytica, 
London, UK
Objectives: To compare physicians and patient’s reports of health resource uti-
lisation using the PGRx-3 datasets. MethOds: PGRx (Pharmacoepidemiologic 
General Research eXtension) is a multiusers, multi-countries, prospective Real 
World Datasets originally assembled for effectiveness and relative risk of medicines 
research. In 2015, PGRx was extended to HEOR research in six countries (France, 
UK, Italy, Germany, Spain and in the US). Diseases studied with the PGRx meth-
odology are: acute coronary syndrome, arrhythmias, stroke, lupus, rheumatoid 
arthritis, multiple sclerosis, Guillain Barré Syndrome, type I diabetes, autoimmune 
thyroiditis, depression and suicide attempts, paediatric autoimmune disorders, 
breast cancer, prostate cancer (on-going) and others. Patients are recruited by board-
certified specialists or general practitioners and they can fill self-questionnaires. 
More than 65% consenting patients also undergo a telephone interview. All PGRx 
datasets are submitted for ethics and privacy protection committees’ approval in 
the contemplated countries. Medical records of more than 5,000 patients have been 
obtained in a series of validation studies including several of the PGRx disorders and 
results compared to interviews of the same patients on health resources and drug 
utilisation. Results: An agreement superior to 95% between patients and their 
physician’s medical records was observed for report of chronic drug use and vac-
cines, but the agreement was low (< 30%) for drugs available OTC or in the patients’ 
pharmacy (eg: NSAIDs) and for patients’ health resources utilisation (eg: physician 
visits) (agreement less than 25%). cOnclusiOns: Physicians have poor knowledge 
of acute drug use and of health resource utilisation by patients. Patient interviews 
are more valid sources of information for health economics and outcomes research 
than chart reviews
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codes as independent variables and the logit of progression degree as a dependent 
variable. Results: 1,436 target patients were extracted from the database. When 
the actual progression degree is over 80%, the estimated progression degree rises 
with the actual degree, however, at the lower progression degrees, the estimated 
degree was excessively overestimated. cOnclusiOns: We have developed a model 
to estimate the progression degree in colon cancer. The model estimates the pro-
gression degree well only for the last phase patients. The model should further be 
improved to minimize the bias at the lower degree.
PRM12
beyOnd The Middle: evAluATing suRROgAcy Of clinicAl TRiAl 
endPOinTs AcROss TRiAl duRATiOns
Wasserman M1, Amin A2
1Double Helix Consulting, New York, NY, USA, 2Double Helix Consulting, London, UK
Objectives: Overall survival (OS) remains the gold standard measure of clini-
cal efficacy for oncology clinical trials due to its objective nature and consistency 
between diseases and treatments. However, given recent advances in treatments, 
and prolonged survival, OS benefits are becoming more challenging to establish, 
requiring more extensive follow-up. A number of methods to test this rationale 
have been developed but these often lack adequate data, relying solely on mean or 
median survival. Recognising these limitations, we developed an alternative meth-
odology whereby surrogacy is established over time, to ensure that a surrogate is 
not only valid at the mean, but also throughout treatment duration. MethOds: A 
number of different survival points were derived from selected oncology trials by 
digitizing available survival curves. PlotDigitizer 2.6.4 software was used to establish 
time points for 10%, 25%, 50%, 75%, and 90% OS and progression-free survival (PFS). 
Correlation and regression analysis were evaluated at these percentiles based on 
survival times. Patient populations between the clinical trials were comparable to 
one another. Statistical analysis was conducted in STATA 12. Results: Correlation 
analysis found the strongest association between PFS and OS between 75% and 
25% survival (0.865 to 0.953; p< 0.01), with a weak association at 90% survival (0.61; 
p= 0.096). Regression analysis also found that PFS had the largest influence on OS 
between 75% and 25% survival (R2> 0.75). cOnclusiOns: Given the varying nature 
of how patients progress across and within types of therapies, it is essential to 
ensure the surrogacy of the endpoint across the full trial duration. For example, 
patients may progress early on in a disease and surrogacy may not be consistent 
across different time points. Additionally, in evaluating older studies, using this 
approach of scanning survival data will provide a richer picture of the disease area 
that may no longer be available from authors or research institutions.
PRM13
neTWORk MeTA-AnAlysis Of MulTiPle OuTcOMes incORPORATing dOse-
RelATed cOnsTRAinTs: APPlicATiOn TO OveRAcTive blAddeR syndROMe
Owen RK, Tincello DG, Bujkiewicz S, Abrams K
University of Leicester, Leicester, UK
bAcKgROund: Overactive bladder(OAB) is characterized by symptoms of urgency, 
incontinence, frequency and nocturia. With the syndromic nature of the condition, 
clinical trials often solely report the most effective outcome i.e. the symptom with 
the largest improvement. As a result different interventions are evaluated for dif-
ferent outcomes, which can have severe implications for network meta-analyses, 
and consequently, decision-making. Objectives: To evaluate the use of multivari-
ate network meta-analysis(MVNMA) to identify the most effective intervention for 
treating OAB syndrome. MethOds: Using Bayesian Markov Chain Monte Carlo 
methods, we developed MVNMA accounting for the correlation between multiple 
outcomes to predict treatment effects for missing data. We extended this model to 
incorporate the exchangeability between treatment effects of the same interven-
tion with different methods of administration (e.g. immediate release, extended 
release, intravesical etc.) and incorporated dose-response constraints on increasing 
doses. The outcomes of interest were mean change from baseline in incontinence, 
and urgency episodes. Results: Independently, the datasets included 109 and 56 
trials, evaluating 93 and 51 interventions, for incontinence and urgency episodes 
respectively. Sacral nerve stimulation appeared to be the most effective intervention 
for reducing incontinence with an estimated mean reduction of -8.9(95%CrI:-10.9,-
7) episodes per 24hours relative to placebo. For urgency, sacral nerve stimulation 
was disconnected from the network and thus could not be not evaluated. Borrowing 
information between outcomes, the dataset for multivariate analyses included 117 
trials evaluating all 95 treatments for OAB. Sacral nerve stimulation appeared to be 
the most effective intervention for both incontinence and urgency episodes with an 
estimated mean reduction of -8.3(95%CrI:-10.1,-6.9) and -9.1(95%CrI:-10.5,-7.3) epi-
sodes, respectively. cOnclusiOns: Sacral nerve stimulation appeared to be the most 
effective intervention for treating OAB symptoms. MVNMA allowed us to evaluate 
all interventions across all outcomes, and in this case also increased precision in 
treatment effect estimates. Further work includes adjustment for baseline severity.
PRM14
The vAlue Of PROgRessiOn-fRee suRvivAl (Pfs) As An endPOinT in 
OncOlOgy TRiAls
Quinn C1, Palmer S2, Bruns J3, Grant C1, Sykes D4, Kaura S5
1PRMA Consulting, Fleet Hampshire, UK, 2University of York, Heslington, York, UK, 3German 
Cancer Society, Berlin, Germany, 4PRMA Consulting, Hampshire, UK, 5Celgene Corporation, 
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Objectives: The clinical endpoints selected for oncology trials have to meet the 
needs of diverse stakeholders: patients, clinicians, regulators, and HTA agencies, each 
with a different perspective. PFS is becoming a more widely accepted measure of 
treatment efficacy, but there is tension between regulators and payors regarding its 
acceptability. This study investigated PFS as a valid and credible endpoint from the 
perspectives of relevant decision-makers. MethOds: Published and gray literature 
(2005–2015) were searched for regulatory and HTA guidance on PFS as an endpoint. 
We identified examples of decisions by regulators and HTA agencies in which PFS 
tended to be protective of discontinuations due to adverse events relative to stand-
ard dose EFV. Use of arm-specific regression supplemented by endonodal trials led 
to tighter confidence intervals facilitating decision-making. Specifically, DTG was 
consequently superior to EFV with respect to CD4 cell counts and raltegravir was 
distinguishable from EFV when it was not otherwise. cOnclusiOns: Making full 
use of available evidence is the focal strength of NMA methodology. Therefore, we 
recommend use of endonodal trials to further supplement evidence bases requiring 
arm-specific meta-regression.
PRM9
cRiTicAl APPRAisAl Of ReAl WORld evidence – A RevieW Of 
RecOMMended And cOMMOnly used TOOls
Quigley JM1, Thompson JC2, Halfpenny NJ2, Scott DA1
1ICON Health Economics and Epidemiology, Oxford, UK, 2ICON Health Economics, Oxford, UK
Objectives: In an absence of randomized controlled trials (RCTs) and to verify RCT 
evidence, health technology assessment (HTA) agencies commonly rely on real-
world (RW) studies to provide efficacy evidence for healthcare interventions. RW 
study designs can introduce considerable bias into a systematic review (SR) and sev-
eral methodologies exist to evaluate the risk of bias in such studies. We conducted a 
series of reviews to identify which tools are commonly used and which are recom-
mended by HTA bodies. MethOds: A targeted search of SRs including RW studies, 
conducted in MEDLINE and EMBASE (OVID SP), identified reviews published January 
2013-June 2015. Studies identified were reviewed to determine which appraisal tool 
was used. Secondly, recommendations for the critical appraisal of RW studies by 
expert review groups (Cochrane, CRD) and HTA bodies (NICE, SMC, NCPE, AWMSG, 
IQWiG, PBAC, AMCP, AHRQ and CADTH) were reviewed. Results: 1885 studies were 
identified and screened. Commonly used tools included Downs & Black, Chalmers, 
the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither Cochrane nor CRD 
recommend a particular risk of bias instrument. The AHRQ developed the MORE 
checklist following a SR of existing critical appraisal tools. Of the other HTA bodies 
only CADTH recommend use of a specific critical appraisal tool; SIGN 50 (for cohort 
or case-control studies). The tools identified examine a variety of criteria including 
reporting, external validity, bias, confounding, and power. cOnclusiOns: There 
is no consensus on a preferred instrument that allows for the assessment of all 
types of RW evidence and critical appraisal of RW evidence is often omitted from 
HTA submissions. There is thus a need for cross communication between groups 
to reach a consensus and develop a suitable tool. Until a suitable tool is developed, 
reviewers should select the most appropriate checklist for the design of the studies 
identified in a particular SR.
PRM10
dOes ATTRiTiOn in subjecT-bAsed sTudies Of dRug sAfeTy leAd TO biAs 
RelATed TO MORbidiTy?
Pignot M1, Klamert A2, Pisa G1, Potthoff P3
1Kantar Health, Munich, Germany, 2Kantar Health Germany, Munich, Germany, 3Kantar Health, 
Munichn, Germany
Objectives: Sample quality in prospective long-term drug safety studies can 
be impaired by selective lost-to-follow-up. Attrition will especially bias the sam-
ple, when patients with relevant risk factors selectively drop out. In this case, 
effects in endpoints cannot be related to study-relevant independent variables. 
The present contribution will demonstrate how careful follow-up procedures can 
prevent disease-related drop-out bias of the sample. MethOds: For a long-term 
prospective safety study of new Oral Contraceptive (OC) 25,213 women aged 20 
to 40 years were enrolled from gynecological practices in Germany. The women 
filled-in a baseline questionnaire and were followed-up over two years with four 
follow-up questionnaires in total. Whenever safety-relevant signs were reported in 
the questionnaires, physicians validated the report. After two years 12,823 women 
were still in the sample and completed the fourth questionnaire. Disease differ-
ences between the “Retained” and the “Lost” group, which could indicate sample 
bias, were analysed using multivariate methods. Results: The “retained” and the 
“lost-to-follow-up” group did not differ in initial disease status or in risk factor at 
study start: High blood pressure: 2.9% in “Retained Group”; 2.7% in “Lost Group” 
(phi= .006; n.s.), diabetes : 0.6% vs. 0.6% (phi= .001; n.s.), high cholesterol: 2.6% vs. 
2.4% (phi= .007; n.s.),venous thrombosis : .8% vs. .8% (phi= .002; n.s.), smoker-rate : 
34.9% vs. 42.3% (phi= .127), BMI> 30: r= .004 (n.s.), age r= .048 (n.s.). The results show 
that drop-out of the initial sample is not related to study relevant morbidity and 
that sample bias cannot be concluded. cOnclusiOns: Careful follow-up methods 
guarantee low lost-to-follow-up in longterm prospective studies of drug safety. 
Since drop-out cannot be attributed to study-relevant confounders, attrition does 
not lead to sample bias.
PRM11
esTiMATiOn Of The PROgRessiOn Of cOlOn cAnceR by jAPAnese  
lARge-scAle insuRAnce benefiTs dATA AnAlysis
Iwasaki K1, Arata H1, Soeda J2, Yanai T2, Hiroi S3
1Milliman, Tokyo, Japan, 2Takeda Pharmaceutical Company Limited, Tokyo, Japan, 3Takeda 
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Objectives: Accurate determination of the progression degree in colon cancer is 
of paramount importance for the decision making in treatment policy. However, 
it had been difficult to extract the exacerbation status from the real-world data. 
The objective of the study was to develop the model to determinate the progres-
sion degree using the insurance benefits data in Japan. MethOds: We conducted 
analyses using claims data provided by Medical Data Vision Co., Ltd. We extracted 
target patients by the criteria those who meets all of the following conditions; 
at least one colon cancer diagnosis (ICD-10 code C18~20), tractable from the first 
diagnosis to death, and have at least 365 days of observation. We set the progression 
degree as a scale from 0% to 100%. The degree of 100% indicates the patient death. 
For the first diagnosis, the scale was adjusted based on the patient’s condition. We 
have developed a linear regression model by using the medication frequency of ATC 
